pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›petosemtamab
drug · antibody
save

petosemtamab

Phase 3updated 6mo ago
by Merus NV🔗 ChEMBL
Phase 3
community read0 votes

Antibody drug with a maximum clinical stage of Phase 1, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

Trials studying petosemtamab

  • phase3A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)active not recruitingn=699
  • phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)recruitingn=600
  • phase3A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)active not recruitingn=621
  • phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancerrecruitingn=960
  • phase2Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancerwithdrawn

News(7)

  • Genmab soars to record highs after cancer drug succeeds in key trial
    The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
    biopharma_dive · 18d ago
  • Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
    Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
    biospace · 19d ago
  • Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
    Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
    biospace · 19d ago
  • Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
    Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…
    fiercebiotech · 19d ago
  • Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
    Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
    biospace · 21d ago
  • ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
    Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.
    fiercebiotech · 23d ago
  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 28d ago
generic
petosemtamab
indication
Recurrent Head And Neck Squamous Cell Carcinoma
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?